Literature DB >> 9622218

The coagulation profile in hepatosplenic schistosomiasis.

N E El-Bassiouni1, A E El Bassiouny, N A Hussein, H H El-Sayed, I M Ibrahim, M G Lotfy, S A Omran.   

Abstract

The biological activity of blood coagulation factors II, V, VII, VIII, IX, X, XI and XII, fibrinogen and prekallikrein was assessed in 15 healthy subjects and 60 patients with endemic Egyptian hepatosplenomegaly. The degree of liver disease was graded according to the Child-Pugh classification, the intensity of S. mansoni infection was monitored by determination of circulating schistosome immune complexes (CSIC) level using a monoclonal antibody and hemostasis activation was detected by measurement of hemostatic markers D-dimer and prothrombin fragment 1 + 2 (F1+2). Functional activity of antithrombin III, alpha2-antiplasmin and protein C as well as quantitative determination of plasma concentrations of alpha1-antitrypsin, C1 activator inhibitor and alpha2-macroglobulin were also carried out. The progressive deterioration of liver function which matched the severity of the disease and the intensity of schistosomal infection led to a reduction in anticoagulant proteins (decreases in antithrombin III and protein C) resulting in hypercoagulability and thrombin generation (increased F1+2) subsequently followed by consumption (prolongation of coagulation screening tests, thrombocytopenia, hypofibrinogenemia and decreased factor VIII resulting in hypocoagulability and secondary fibrinolysis (increased D-dimer and decreased alpha2-antiplasmin). A significant decline in fibrinogen and factors VII, XII and prekallikrein was detected in bleeders compared with ascitic patients. The decline in factor XII was closely related to CSIC high titers in all disease groups, but was not correlated to D-dimer or F1+2 concentrations. This suggests that circulating schistosome immune complexes may exert an inhibitory effect on contact factor XII which should be taken into account when considering the reasons for schistosomal coagulopathy and bleeding in hepatosplenic schistosomiasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9622218     DOI: 10.1097/00001721-199803000-00011

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

1.  The impact of schistosomes and schistosomiasis on murine blood coagulation and fibrinolysis as determined by thromboelastography (TEG).

Authors:  Akram A Da'dara; Armelle M de Laforcade; Patrick J Skelly
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

2.  Trypsin- and Chymotrypsin-like serine proteases in schistosoma mansoni-- 'the undiscovered country'.

Authors:  Martin Horn; Pavla Fajtová; Liliana Rojo Arreola; Lenka Ulrychová; Pavla Bartošová-Sojková; Zdeněk Franta; Anna V Protasio; David Opavský; Jiří Vondrášek; James H McKerrow; Michael Mareš; Conor R Caffrey; Jan Dvořák
Journal:  PLoS Negl Trop Dis       Date:  2014-03-27

Review 3.  Interference with the host haemostatic system by schistosomes.

Authors:  Mirjam M Mebius; Perry J J van Genderen; Rolf T Urbanus; Aloysius G M Tielens; Philip G de Groot; Jaap J van Hellemond
Journal:  PLoS Pathog       Date:  2013-12-26       Impact factor: 6.823

4.  A case control study on the structural equation model of the mechanism of coagulation and fibrinolysis imbalance in chronic schistosomiasis.

Authors:  Aiping Le; Lunli Zhang; Wei Liu; Xiaopeng Li; Jianwei Ren; An Ning
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

Review 5.  Schistosome Egg Migration: Mechanisms, Pathogenesis and Host Immune Responses.

Authors:  Alice H Costain; Andrew S MacDonald; Hermelijn H Smits
Journal:  Front Immunol       Date:  2018-12-20       Impact factor: 7.561

6.  Basic Coagulation Profiles and Platelet Count Among Schistosoma mansoni-Infected Adults Attending Sanja Primary Hospital, Northwest Ethiopia.

Authors:  Tahir Eyayu; Ayalew Jejaw Zeleke; Masresha Seyoum; Ligabaw Worku
Journal:  Res Rep Trop Med       Date:  2020-04-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.